[HTML][HTML] Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223–enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis

Y He, RM Rodrigues, X Wang, W Seo… - The Journal of …, 2021 - Am Soc Clin Investig
Y He, RM Rodrigues, X Wang, W Seo, J Ma, S Hwang, Y Fu, E Trojnár, C Mátyás, S Zhao…
The Journal of clinical investigation, 2021Am Soc Clin Investig
Neutrophil infiltration around lipotoxic hepatocytes is a hallmark of nonalcoholic
steatohepatitis (NASH); however, how these 2 types of cells communicate remains obscure.
We have previously demonstrated that neutrophil-specific microRNA-223 (miR-223) is
elevated in hepatocytes to limit NASH progression in obese mice. Here, we demonstrated
that this elevation of miR-223 in hepatocytes was due to preferential uptake of miR-223–
enriched extracellular vesicles (EVs) derived from neutrophils as well other types of cells …
Neutrophil infiltration around lipotoxic hepatocytes is a hallmark of nonalcoholic steatohepatitis (NASH); however, how these 2 types of cells communicate remains obscure. We have previously demonstrated that neutrophil-specific microRNA-223 (miR-223) is elevated in hepatocytes to limit NASH progression in obese mice. Here, we demonstrated that this elevation of miR-223 in hepatocytes was due to preferential uptake of miR-223–enriched extracellular vesicles (EVs) derived from neutrophils as well other types of cells, albeit to a lesser extent. This selective uptake was dependent on the expression of low-density lipoprotein receptor (LDLR) on hepatocytes and apolipoprotein E (APOE) on neutrophil-derived EVs, which was enhanced by free fatty acids. Once internalized by hepatocytes, the EV-derived miR-223 acted to inhibit hepatic inflammatory and fibrogenic gene expression. In the absence of this LDLR- and APOE-dependent uptake of miR-223–enriched EVs, the progression of steatosis to NASH was accelerated. In contrast, augmentation of this transfer by treatment with an inhibitor of proprotein convertase subtilisin/kexin type 9, a drug used to lower blood cholesterol by upregulating LDLR, ameliorated NASH in mice. This specific role of LDLR and APOE in the selective control of miR-223–enriched EV transfer from neutrophils to hepatocytes may serve as a potential therapeutic target for NASH.
The Journal of Clinical Investigation